AU2003274822B2 - Intracellular delivery of biological effectors - Google Patents

Intracellular delivery of biological effectors Download PDF

Info

Publication number
AU2003274822B2
AU2003274822B2 AU2003274822A AU2003274822A AU2003274822B2 AU 2003274822 B2 AU2003274822 B2 AU 2003274822B2 AU 2003274822 A AU2003274822 A AU 2003274822A AU 2003274822 A AU2003274822 A AU 2003274822A AU 2003274822 B2 AU2003274822 B2 AU 2003274822B2
Authority
AU
Australia
Prior art keywords
peptide
transporter
effector
multimeric
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003274822A
Other languages
English (en)
Other versions
AU2003274822A1 (en
Inventor
Christophe Bonny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xigen SA
Original Assignee
Xigen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen SA filed Critical Xigen SA
Publication of AU2003274822A1 publication Critical patent/AU2003274822A1/en
Assigned to XIGEN SA reassignment XIGEN SA Request for Assignment Assignors: Universtiry of Lausanne
Application granted granted Critical
Publication of AU2003274822B2 publication Critical patent/AU2003274822B2/en
Priority to AU2008201592A priority Critical patent/AU2008201592C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2003274822A 2002-06-07 2003-06-06 Intracellular delivery of biological effectors Ceased AU2003274822B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008201592A AU2008201592C1 (en) 2002-06-07 2008-04-10 Intracellular Delivery of Biological Effectors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/165,015 US7033597B2 (en) 2000-10-13 2002-06-07 Intracellular delivery of biological effectors
US10/165,015 2002-06-07
PCT/IB2003/003097 WO2003103718A2 (en) 2002-06-07 2003-06-06 Intracellular delivery of biological effectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008201592A Division AU2008201592C1 (en) 2002-06-07 2008-04-10 Intracellular Delivery of Biological Effectors

Publications (2)

Publication Number Publication Date
AU2003274822A1 AU2003274822A1 (en) 2003-12-22
AU2003274822B2 true AU2003274822B2 (en) 2008-01-17

Family

ID=29732051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003274822A Ceased AU2003274822B2 (en) 2002-06-07 2003-06-06 Intracellular delivery of biological effectors

Country Status (6)

Country Link
US (2) US7033597B2 (https=)
EP (1) EP1511763A2 (https=)
JP (2) JP4514607B2 (https=)
AU (1) AU2003274822B2 (https=)
CA (1) CA2488716A1 (https=)
WO (1) WO2003103718A2 (https=)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US20040248158A1 (en) * 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2004073650A2 (en) 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
WO2004094463A2 (en) * 2003-04-18 2004-11-04 University Of Florida Research Foundation, Inc. Peptide inhibitors of autophosphorylation protein kinases
AU2004270655B2 (en) 2003-08-13 2011-03-24 University Of South Florida Methods for inhibiting tumor cell proliferation
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
US8669376B2 (en) 2004-02-17 2014-03-11 University Of South Florida Cytotoxin compounds and methods of isolation
CA2556550A1 (en) 2004-02-17 2005-09-01 University Of South Florida Cytotoxin compound and method of isolation
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2007047623A2 (en) * 2005-10-14 2007-04-26 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
US8071540B2 (en) * 2007-07-13 2011-12-06 University of Pittsburgh—of the Commonwealth System of Higher Education Virus derived antimicrobial peptides
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US8673910B2 (en) * 2008-06-30 2014-03-18 H. Lee Moffitt Cancer Center And Research Institute Proteasome inhibitors for selectively inducing apoptosis in cancer cells
WO2010011666A2 (en) * 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
CA2733126A1 (en) 2008-08-05 2010-02-11 University Of South Florida Methods of treating cognitive impairment
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011008863A2 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
WO2011130740A2 (en) 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9409868B2 (en) 2012-01-24 2016-08-09 H. Lee Moffin Cancer Center and Research Institute, Inc. Inhibitors of rho associated protein kinases (ROCK) and methods of use
JP6233812B2 (ja) 2012-03-07 2017-11-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 選択的ヒストンデアセチラーゼ６阻害剤
US10098967B2 (en) 2012-12-03 2018-10-16 Ohio State Innovation Foundation Self-assembly of therapeutic agent-peptide nanostructures
EP2928502B1 (en) * 2012-12-05 2019-01-23 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
JP6456853B2 (ja) * 2013-03-13 2019-01-23 ビオクリネ エービー 糖尿病を治療および／または発症を制限するための方法
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3030241A4 (en) 2013-08-06 2019-06-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. INHIBITORS OF ACK1 / TNK2.TYROSINE KINASE
WO2015025323A1 (en) 2013-08-21 2015-02-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mood and stress related disorders
US10626178B2 (en) 2013-08-21 2020-04-21 Raz Yirmiya Treatment of mood and stress related disorders
EP3689420A1 (en) 2014-01-23 2020-08-05 H. Lee Moffitt Cancer Center & Research Institute, Inc. Icariin derivatives for use in treating myelodysplasia syndrome
DK3096775T5 (da) 2014-01-24 2024-10-14 Univ Florida SOCS-mimetika til behandling af sygdomme
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
US10197575B2 (en) 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
JP6807831B2 (ja) 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US10118942B2 (en) 2015-03-26 2018-11-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Toll-like receptor 2 ligands and methods of making and using thereof
US20180126013A1 (en) 2015-05-06 2018-05-10 H.Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target mc1r
US10995140B2 (en) 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
CN108348779A (zh) 2015-08-02 2018-07-31 H·李·莫菲特癌症中心研究有限公司 Ack1/tnk2酪氨酸激酶的抑制剂
CN108884124A (zh) 2015-09-17 2018-11-23 俄亥俄州创新基金会 碳硼烷化合物及其使用方法
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
EP3387133B1 (en) 2015-12-09 2021-11-17 Vanderbilt University Biosynthesis of everninomicin analogs in micromonospora carbonacea var aurantiaca
WO2017156527A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
BR112018068906A2 (pt) 2016-03-16 2019-01-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
RU2018142711A (ru) 2016-05-04 2020-06-04 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Средство для целенаправленного воздействия на дельта-опиоидный рецептор для молекулярной визуализации и иммунотерапии рака
US11351222B2 (en) 2016-11-09 2022-06-07 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
WO2018098282A2 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
TW202500573A (zh) 2016-11-22 2025-01-01 俄亥俄州立創新基金會 細胞穿透肽序列
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11583525B2 (en) 2017-06-06 2023-02-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Geranylgeranyltransferase I inhibitor for treatment of a PTEN defective cancer
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN117567639A (zh) 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
US11814341B2 (en) 2018-05-04 2023-11-14 Ohio State Innovation Foundation Non-peptidic cell-penetrating motifs
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN112512589A (zh) 2018-07-11 2021-03-16 H·李·莫菲特癌症中心研究有限公司 二聚体免疫调节化合物对抗基于cereblon的机制
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
US11987568B2 (en) 2018-08-03 2024-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Allosteric inhibitor of WEE1 kinase
WO2020037116A1 (en) 2018-08-17 2020-02-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors
WO2020081918A2 (en) 2018-10-18 2020-04-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Βeta-catenin and b-cell lymphoma 9 (bcl9) inhibitors
US12600710B2 (en) 2018-10-18 2026-04-14 Lee Moffitt Cancer Center and Research Institute, Inc. Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors
WO2020118179A1 (en) 2018-12-07 2020-06-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptidomimetic inhibitors of β-catenin/tcf protein–protein interaction
JP2023501385A (ja) 2019-11-08 2023-01-18 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗微生物ペプチドを含む組成物
EP4058032A4 (en) 2019-12-19 2024-01-10 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds
KR102811112B1 (ko) 2020-01-20 2025-05-21 삼성전자주식회사 매립형 공기청정장치
US20230097866A1 (en) 2020-01-24 2023-03-30 Ohio State Innovation Foundation Bacterial topoisomerase inhibitors derived from isomannide
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
EP4314016A1 (en) 2021-03-31 2024-02-07 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections
WO2022240760A2 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
EP4337263A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
AU2022271873A1 (en) 2021-05-10 2024-01-04 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
AU2022298774A1 (en) 2021-06-23 2023-12-14 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
MX2024002640A (es) 2021-09-01 2024-07-19 Entrada Therapeutics Inc Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
WO2023219933A1 (en) 2022-05-09 2023-11-16 Entrada Therapeutics, Inc. Compositions and methods for delivery of nucleic acid therapeutics
IL318248A (en) 2022-07-15 2025-03-01 Entrada Therapeutics Inc Hybrid oligonucleotides
WO2024073042A1 (en) 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents
WO2024115720A1 (en) * 2022-12-01 2024-06-06 Hairvel Oü Novel peptide conjugates
WO2025038901A1 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
AU2024325879A1 (en) 2023-08-17 2026-03-12 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides
WO2025072246A1 (en) 2023-09-26 2025-04-03 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 50 in duchenne muscular dystrophy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
FR2767323A1 (fr) * 1997-08-12 1999-02-19 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2000012587A2 (en) * 1998-08-28 2000-03-09 Gryphon Sciences Polyamide chains of precise length, methods to manufacture them and their conjugates
WO2002031109A2 (en) * 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131620A1 (en) * 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
WO1993019768A1 (en) * 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
US6630351B1 (en) * 1999-06-07 2003-10-07 Mirus Corporation Compositions and methods for drug delivery using pH sensitive molecules
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
JP4129298B2 (ja) 1997-05-15 2008-08-06 サイトジェン コーポレーション 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法
CN1263473A (zh) * 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
FR2767323A1 (fr) * 1997-08-12 1999-02-19 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2000012587A2 (en) * 1998-08-28 2000-03-09 Gryphon Sciences Polyamide chains of precise length, methods to manufacture them and their conjugates
WO2002031109A2 (en) * 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences

Also Published As

Publication number Publication date
US20060178310A1 (en) 2006-08-10
EP1511763A2 (en) 2005-03-09
CA2488716A1 (en) 2003-12-18
US7033597B2 (en) 2006-04-25
WO2003103718A2 (en) 2003-12-18
JP2006500917A (ja) 2006-01-12
AU2003274822A1 (en) 2003-12-22
US20030032594A1 (en) 2003-02-13
WO2003103718A3 (en) 2004-11-25
JP2010024250A (ja) 2010-02-04
JP4514607B2 (ja) 2010-07-28

Similar Documents

Publication Publication Date Title
AU2003274822B2 (en) Intracellular delivery of biological effectors
US7034109B2 (en) Intracellular delivery of biological effectors
AU723694B2 (en) Exendin analogues, processes for their preparation and medicaments containing them
JPH06505486A (ja) βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
CN101107266A (zh) 具有神经肽-2受体（y2r）激动剂活性的肽类
US20150038671A1 (en) Efficient Synthesis of CN2097 and RC7 and Their Analogs
Ciulla et al. Nature-inspired and medicinally relevant short peptides
TWI726844B (zh) 胜肽載體上之多重寡核苷酸部分
Parthasarathy et al. The medicinal chemistry of therapeutic peptides: Recent developments in synthesis and design optimizations
Konieczny et al. N-terminus to arginine side-chain cyclization of linear peptidic neuropeptide Y Y4 receptor ligands results in picomolar binding constants
Appiah Kubi et al. Designing cell-permeable macrocyclic peptides
JP3805679B2 (ja) 新規のｌｈｒｈ拮抗物質、その製造および医薬としてのその使用
AU2008201592B2 (en) Intracellular Delivery of Biological Effectors
Shi et al. α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo
CA2606894A1 (en) Novel compounds as glp-i agonists
JP4927746B2 (ja) 樹脂上ペプチド環化
AU2007216926A1 (en) Intracellular Delivery of Biological Effectors by Novel Transporter Peptide Sequences
Einsiedel et al. Development of disulfide-functionalized peptides covalently binding G protein-coupled receptors
CN101223189A (zh) 作为glp-i激动剂的新颖化合物
Chen et al. Chemobodies as Targeting Moieties of Insulin-Secreting Cells
Zamudio Vázquez Synthesis, Biological Evaluation and Insights into the Mode of Action of Quinoxaline Containing Peptides
Jessop Molecular transporters for drug delivery: Guanidinium-based and nanotube transporters

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: XIGEN SA

Free format text: FORMER APPLICANT(S): UNIVERSTIRY OF LAUSANNE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired